Mazen Dimachkie

Financial relationships

Disclosure for Mazen Dimachkie

Disclosure

Yes, I have had a relevant financial relationship within the past 12 months.
Financial relationships: 
Attribution: 
Self
Type of financial relationship: 
Grant Or Contract
Commercial interest: 
Dr. Dimachkie received research grants or contracts from Alexion, Alnylam Pharmaceuticals, Amicus, Biomarin, Bristol-Myers Squibb, Catalyst, Corbus, CSL-Behring, FDA/OOPD, GlaxoSmithKline, Genentech, Grifols, Kezar, Mitsubishi Tanabe Pharma, MDA, NIH.
Attribution: 
Self
Type of financial relationship: 
Independent contractor
Commercial interest: 
Dr. Dimachkie serves or recently served as a consultant for ArgenX, Catalyst, Cello, CSL-Behring, EcoR1, Kezar, Momenta, NuFactor, Octapharma, RMS Medical, Sanofi Genzyme, Shire Takeda, Spark Therapeutics and UCB Biopharma.
Attribution: 
Self
Type of financial relationship: 
Grant Or Contract
Commercial interest: 
Dr. Dimachkie received research grants or contracts from Novartis, Octapharma, Orphazyme, Ra Pharma/UCB, Sanofi Genzyme, Sarepta Therapeutics, Shire Takeda, Spark, UCB Biopharma, Viromed/Healixmith & TMA.
Return to 42nd Annual Carrell Krusen Neuromuscular Symposium (RP2002B)